title: Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
abstract: OBJECTIVE
  The pharmacology, pharmacokinetics, safety, efficacy, and dosing recommendations of vedolizumab, an integrin-receptor antagonist for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), are reviewed.
  
  
  CONCLUSIONS
  Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease who have had an inadequate response with, lost response to, or were intolerant to anti-tumor necrosis factor (TNF) agents or immunomodulators or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Phase III clinical trials have demonstrated efficacy in achieving remission as induction and maintenance therapy in CD and UC. Remission was also achieved at week 10 in patients with CD in whom previous treatment with anti-TNF agents had failed. Adverse effects of vedolizumab include nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in the extremities. To date, no cases of progressive multifocal leukoencephalopathy (PML) have been reported. The recommended dose of vedolizumab in adults with UC or CD is 300 mg administered via intravenous infusion at zero, two, and six weeks, followed by every eight weeks. The average wholesale unit price is $5782.80, but a patient assistance program is available.
  
  
  CONCLUSIONS
  Vedolizumab is a new alternative for patients with moderate-to-severe UC or CD, as well as patients who have not responded to anti-TNF agents. The current safety profile and lack of reported PML make it a promising addition to the treatment of these conditions.
authors.affiliation: Lindsay Hahn, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Ashton Beggs, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; Kristy Wahaib, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Leela Kodali, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; and Vanessa Kirkwood is a Pharm.D. student, College of Pharmacy, Belmont University, Nashville, TN.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Hahn
authors.affiliation: Lindsay Hahn, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Ashton Beggs, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; Kristy Wahaib, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Leela Kodali, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; and Vanessa Kirkwood is a Pharm.D. student, College of Pharmacy, Belmont University, Nashville, TN.
authors.forename: Ashton
authors.initials: A
authors.lastname: Beggs
authors.affiliation: Lindsay Hahn, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Ashton Beggs, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; Kristy Wahaib, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Leela Kodali, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; and Vanessa Kirkwood is a Pharm.D. student, College of Pharmacy, Belmont University, Nashville, TN.
authors.forename: Kristy
authors.initials: K
authors.lastname: Wahaib
authors.affiliation: Lindsay Hahn, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Ashton Beggs, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; Kristy Wahaib, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Leela Kodali, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; and Vanessa Kirkwood is a Pharm.D. student, College of Pharmacy, Belmont University, Nashville, TN.
authors.forename: Leela
authors.initials: L
authors.lastname: Kodali
authors.affiliation: Lindsay Hahn, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Ashton Beggs, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; Kristy Wahaib, Pharm.D., BCPS, is Assistant Professor of Pharmacy Practice; Leela Kodali, Pharm.D., BCACP, is Assistant Professor of Pharmacy Practice; and Vanessa Kirkwood is a Pharm.D. student, College of Pharmacy, Belmont University, Nashville, TN.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Kirkwood
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D016023:Integrins / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016023:Integrins; C543529:vedolizumab